Literature DB >> 28889760

An analysis of clinical characteristics and patient outcomes in primary mediastinal sarcomas.

Omar Abdel-Rahman1.   

Abstract

BACKGROUND: Published data concerning primary mediastinal sarcomas are limited to small-sized retrospective series.  This study reviewed the clinical outcomes of these cases from the SEER (surveillance, epidemiology and end results) database.
METHODS: Primary mediastinal sarcomas (1988 - 2013) were assembled from the SEER database. The incidence and 10-year cancer-specific survival rates were compared to other primary mediastinal malignancies (thymic carcinoma, germ cell tumors, neurogenic tumors, Hodgkin / non Hodgkin lymphomas) as well as to non mediastinal sarcomas.
RESULTS: A total of 204 patients were recruited into this cohort. Multivariate analysis showed better overall survival for patients with younger age at diagnosis, low grade [hazard ratio 0.427 (95% CI: 0.224-0.814; P= 0.010)], posterior mediastinum location [hazard ratio 0.458 (95% CI: 0.268-0.781; P= 0.004)], node negative disease [hazard ratio 0.463 (95% CI: 0.232-0.923; P= 0.029)] and surgical treatment [hazard ratio 0.488 (95% CI: 0.336-0.709; P <0.0001)]. Compared to other mediastinal malignancies, primary mediastinal sarcomas have the worst 10-year overall survival. Similarly compared to non mediastinal sarcomas, primary mediastinal sarcomas have worse 10-year overall survival (23% versus 55%).
CONCLUSION: Primary mediastinal sarcoma is a rare entity with worse prognosis compared to non-mediastinal counterparts. Surgical resection plays a particularly important role in the management.

Entities:  

Keywords:  Mediastinal tumor; epidemiology; sarcoma; survival

Mesh:

Year:  2017        PMID: 28889760     DOI: 10.1080/14737140.2017.1378576

Source DB:  PubMed          Journal:  Expert Rev Anticancer Ther        ISSN: 1473-7140            Impact factor:   4.512


  6 in total

1.  Long-term survival of patients with central or > 7 cm T4 N0/1 M0 non-small-cell lung cancer treated with definitive concurrent radiochemotherapy in comparison to trimodality treatment.

Authors:  Nika Guberina; Christoph Pöttgen; Martin Schuler; Maja Guberina; Georgios Stamatis; Till Plönes; Martin Metzenmacher; Dirk Theegarten; Thomas Gauler; Kaid Darwiche; Clemens Aigner; Wilfried E E Eberhardt; Martin Stuschke
Journal:  Radiat Oncol       Date:  2022-07-16       Impact factor: 4.309

2.  Undifferentiated high-grade pleomorphic sarcoma of the mediastinum.

Authors:  Takashin Nakayama; Yohei Numasawa; Kohei Hashimoto; Keita Hirano
Journal:  Oxf Med Case Reports       Date:  2019-09-28

3.  Treatment Approaches and Outcomes for Primary Mediastinal Sarcoma: Analysis of 976 Patients.

Authors:  Kathryn E Engelhardt; Malcolm M DeCamp; Anthony D Yang; Karl Y Bilimoria; David D Odell
Journal:  Ann Thorac Surg       Date:  2018-05-02       Impact factor: 4.330

4.  Rare, rarer, rarest: lessons from the largest retrospective study to date on mediastinal sarcomas.

Authors:  Michael A den Bakker; Philipp Ströbel
Journal:  Mediastinum       Date:  2019-09-20

Review 5.  The role of molecular pathology in mediastinal sarcomas.

Authors:  David Ilan Suster
Journal:  Mediastinum       Date:  2020-12-30

Review 6.  Mediastinal sarcomas: experience using fine needle aspiration cytopathology.

Authors:  Abberly A Lott-Limbach; Paul E Wakely
Journal:  Mediastinum       Date:  2020-06-30
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.